NCT02910635View on ClinicalTrials.gov

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 19, 2016

Primary Completion Date

December 20, 2016

Study Completion Date

December 20, 2016

Conditions
Abnormalities, Cardiovascular
Interventions
DRUG

Volanesorsen

ISIS 304801 is supplied as 200mg of volanesorsen with 1.0mL of solution per vial

DRUG

Moxifloxacin

Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose

DRUG

Placebo

Trial Locations (1)

75247

Covance, Dallas

Sponsors

Collaborators (1)

Akcea Therapeutics
All Listed Sponsors
collaborator

Akcea Therapeutics

INDUSTRY

lead

Ionis Pharmaceuticals, Inc.

INDUSTRY